Axen Cancer Panel 1, FFPE tissue
Coming soon
A focused 88-gene tumour panel run on preserved (FFPE) tumour tissue, with fusion detection for ALK, RET and ROS1.
| Clinical purpose | Looks for somatic variants, fusions and copy-number changes in well-characterised cancer genes, to support discussion of targeted treatment options. |
|---|---|
| Sample type | FFPE tumour tissue |
| Genes / regions covered | 88 genes for SNVs and indels, plus ALK, RET and ROS1 fusions: ABL1, AKT1, AKT3, ALK, APC, AR, ATM, AXL, BRAF, BRCA1, BRCA2, CCND1, CDH1, CDK4, CDK6, CDKN2A, CEBPA, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, EZH2, FANCA, FANCC, FANCF, FANCG, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MAP2K4, MET, MLH1, MPL, MTOR, MYC, MYCN, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PIK3CA, PIK3R1, PPARG, PTEN, PTPN11, RAF1, RB1, RET, ROS1, RUNX1, SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL, WT1 |
| Intended use | Somatic (tumour) profiling for a defined clinical question. |
| Approximate turnaround | Confirmed when you enquire |
| Report type | NGS report with sequencing quality metrics, SNV/indel, fusion and copy-number sections |
| Ordering requirements | Confirmed when you enquire |
| Price | Confirmed when you enquire |
Turnaround, price and sample requirements are confirmed when you enquire, so you never rely on an outdated figure. Whether this test is appropriate is a decision for the treating oncologist.